Geneva, Switzerland - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for ...
Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today ...
Addex Provisional 2024 Half-Year and Second Quarter Result increased from a Net loss to a Net Profit
Geneva, Switzerland, September 19, 2024-Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric ...
Geneva, Switzerland, September 25, 2026-Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company developing novel small molecule allosteric modulators for ...
Participants are required to register in advance of the conference using the link provided below. Upon registering, each participant will be provided with Participant Dial-in numbers, and a unique ...
Tuesday, Addex Therapeutics Ltd (NASDAQ:ADXN) stock is trading higher with a session volume of 3.79 million versus the average volume of 4.16K as per data from Benzinga Pro. Addex Therapeutics and ...
Geneva, Switzerland - June 30, 2025 - Addex Therapeutics (SIX: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for ...
Geneva, Switzerland, September 24, 2026-Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results